Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
2000 1
2002 1
2003 1
2006 1
2011 1
2014 2
2015 3
2016 2
2017 2
2018 2
2019 2
2020 2
2021 3
2022 4
2023 4
2024 4
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC).
Lapenta C, Santini SM, Antonacci C, Donati S, Cecchetti S, Frittelli P, Catalano P, Urbani F, Macchia I, Spada M, Vitale S, Michelini Z, Corsi DC, Zeuner A, Dattilo R, Tamburo De Bella M. Lapenta C, et al. Among authors: corsi dc. Vaccines (Basel). 2024 Sep 17;12(9):1058. doi: 10.3390/vaccines12091058. Vaccines (Basel). 2024. PMID: 39340087 Free PMC article.
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: corsi dc. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.
Conte PF, Dieci MV, Bisagni G, Schmid P, Zambelli A, Piacentini F, De Laurentiis M, Favaretto AG, Tamberi S, Bianchi GV, Zamagni C, Cinieri S, Corsi DC, Del Mastro L, Ferro A, Gennari A, Mion M, Musolino A, Nicolé L, Del Bianco P, De Salvo GL, Guarneri V. Conte PF, et al. Among authors: corsi dc. Ann Oncol. 2025 Aug 28:S0923-7534(25)00925-1. doi: 10.1016/j.annonc.2025.08.005. Online ahead of print. Ann Oncol. 2025. PMID: 40885530 Free article.
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study.
Giuffrè GM, Carbognin L, Masone Iacobucci G, Gistro M, Tanzilli A, Morganti V, Fuso P, Raffaele M, Rossi V, Paris I, Palazzo A, Corsi DC, Villani V, Moffa F, Cercato MC, Perrone M, Massimiani G, Gerace C, Giannarelli D, Marra C, Fabi A. Giuffrè GM, et al. Among authors: corsi dc. Breast Cancer Res Treat. 2025 Oct;213(3):385-395. doi: 10.1007/s10549-025-07788-2. Epub 2025 Jul 29. Breast Cancer Res Treat. 2025. PMID: 40731102
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.
Signorelli C, Calegari MA, Anghelone A, Passardi A, Gallio C, Bittoni A, Lucchetti J, Angotti L, Di Giacomo E, Zurlo IV, Morelli C, Dell'Aquila E, Artemi A, Gemma D, Emiliani A, Ribelli M, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Chilelli MG, Schirripa M, Schietroma F, Morandi MG, Santamaria F, Dettori M, Cosimati A, Saltarelli R, Minelli A, Lucci-Cordisco E, Basso M. Signorelli C, et al. Among authors: corsi dc. Cancers (Basel). 2025 Jun 18;17(12):2037. doi: 10.3390/cancers17122037. Cancers (Basel). 2025. PMID: 40563686 Free PMC article.
Large Scale Genome-Centric Metagenomic Data from the Gut Microbiome of Food-Producing Animals and Humans.
Lemos LN, de Carvalho FM, Santos FF, Valiatti TB, Corsi DC, de Oliveira Silveira AC, Gerber A, Guimarães APC, de Oliveira Souza C, Brasiliense DM, Maia Castelo-Branco DSC, Anzai EK, Bessa-Neto FO, de Melo GM, de Souza GH, Ferraz LFC, de Nazaré Miranda Bahia M, Mattos MS, da Silva RGB, Veiga R, Simionatto S, Monteiro WAP, de Oliveira Lima WA, Kiffer CRV, Cayô R, Gales AC, de Vasconcelos ATR. Lemos LN, et al. Among authors: corsi dc. Sci Data. 2022 Jun 25;9(1):366. doi: 10.1038/s41597-022-01465-5. Sci Data. 2022. PMID: 35752638 Free PMC article.
Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models.
Becattini C, Vedovati MC, Colombo S, Vanni S, Abrignani MG, Scardovi AB, Marrazzo A, Borselli M, Barchetti M, Fabbri A, Dentali F, Maggioni AP, Agnelli G, Gulizia MM; COntemporary management of Pulmonary Embolism (COPE) Investigators. Becattini C, et al. J Thromb Haemost. 2024 Sep;22(9):2502-2513. doi: 10.1016/j.jtha.2024.04.025. Epub 2024 May 27. J Thromb Haemost. 2024. PMID: 38810699 Free article.
42 results